Fig 1: β-Elemene suppresses U251 cell tumorigenicity in vivo. Five- to six-week old female nude mice were injected subcutaneously with (1 × 107) U251 cells and the tumor weights from the β-elemene-treated group and control group (untreated group) were measured at 28 days post-injection (A).The tumorigenicity of the U251 cells was remarkably reduced in the group that was treated with β-elemene as compared to the group that was not treated with β-elemene (p <0.05) (B). Immunohistochemistry staining of RNF135 of the tumors treated with β-elemene and not treated with β-elemene (control group), original magnification ×400, ×100 (C).
Fig 2: The expression level of RNF135 is suppressed in human glioblastoma cell lines U251, U118, U87 and A172 treated with β-elemene. The data from qRT-PCR (Author: see Abstract) of three independent experimental groups showed that the cell lines treated with β-elemene have a lower level of RNF 135 mRNA than the control group (p <0.05) (A-D). The data from Western blot also confirmed that protein levels of RNF135 were lower in the cell lines that were treated with β-elemene than those of the control group (E-H). Glyceraldehyde 3-phosphate dehydrogenase was used for both qRT-PCR and Western blot as loading control.
Supplier Page from Abcam for Anti-RNF135 antibody